How much does a box of molotinib cost?

Molotinib is mainly used to treat moderate or high-risk myelofibrosis (MF), which is a rare myeloproliferative tumor characterized by excessive proliferation of fibrous tissue and hematopoietic cells in the bone marrow, resulting in impairment of normal hematopoietic function. Molotinib helps slow disease progression by inhibiting abnormal cell signaling.

Molotinib is particularly suitable for patients with intermediate- and high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis (such as myelofibrosis caused after polycythemia vera and essential thrombocythemia) with symptoms of anemia. These patients usually experience symptoms such as thrombocytopenia, red blood cell count, and anemia, which seriously affect their quality of life.

In clinical trials, molotinib has demonstrated significant efficacy, improving patients' anemia symptoms, reducing the need for blood transfusions, and reducing spleen enlargement. At the same time, the safety of the drug has also been verified, but patients still need to pay attention to possible side effects, such as thrombocytopenia, bleeding, bacterial infection, etc., and follow the doctor's guidance when taking the medication.

Currently, molotinib is not available in the domestic market, so patients need to rely on overseas purchasing channels to obtain this drug. According to reliable sources, the original version of molotinib with a specification of 100mg*30 tablets can already be purchased in overseas markets, and its price is as high as 220,000 yuan. At the same time, overseas markets also provide more affordable generic drug options for molotinib, such as the generic drug launched by Laos Lucius Pharmaceutical Company, which is very affordable and can be easily purchased for less than 3,000 yuan. For more questions or needs about molotinib, it is recommended that patients promptly consult a regular overseas medical consulting company to obtain professional answers and help.

In summary, molotinib provides a new and effective treatment option for intermediate- and high-risk myelofibrosis patients with anemia, and is expected to help patients improve their quality of life and delay disease progression.